The EGFR tyrosine kinase inhibitor tyrphostin AG- 1478 causes hypomagnesemia and cardiac dysfunction

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 8, 2012, Pages 1145-1149

  Weglicki, William B ^a,b   Kramer, Jay H ^a   Spurney, Christopher F ^c   Chmielinska, Joanna J ^a   Mak, I Tong ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cardiac dysfunction; EGFR tyrosine kinase inhibitor; Hypomagnesemia; Neutrophil activation; Oxidative stress

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 8 ISOPROSTANE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; MAGNESIUM; OXYGEN RADICAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG EFFECT; DRUG MECHANISM; HEART DISEASE; HEART INJURY; HYPOMAGNESEMIA; LIPID PEROXIDATION; MAGNESIUM BLOOD LEVEL; MALE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SYSTOLIC DYSFUNCTION;

ANIMALS; BIOLOGICAL MARKERS; CALCIUM; DINOPROST; ECHOCARDIOGRAPHY; ENZYME INHIBITORS; GLUTATHIONE; MALE; OXIDATIVE STRESS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RENAL TUBULAR TRANSPORT, INBORN ERRORS; SUPEROXIDES; TYRPHOSTINS;

EID: 84864200196     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-023     Document Type: Article

References (18)

1. Altura, B.T., Wilimzig, C., Trnovec, T., Nyulassy, S., and Altura, B.M. 1994. Comparative effects of a Mg-enriched diet and different orally administered magnesium oxide preparations on ionized Mg, Mg metabolism and electrolytes in serum of human volunteers. J. Am. Coll. Nutr. 13(5): 447-454. PMID:7836622.
2. Atrakchi, A.H., Bloom, S., Dickens, B.F., Mak, I.T., andWeglicki, W.B. 1992. Hypomagnesemia and isoproterenol cardiomyopathies: protection by probucol. J. Cardiovasc. Pathol. 1(2): 155-160. doi:10.1016/1054-8807(92)90019-K.
3. Barbagallo, M., Belvedere, M., and Dominguez, L.J. 2009. Magnesium homeostasis and aging. Magnes. Res. 22(4): 235-246. PMID:20228001.
4. Barrick, C.J., Yu, M., Chao, H.-H., and Threadgill, D.W. 2008. Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice. Toxicol. Appl. Pharmacol. 228(3): 315-325. doi:10.1016/j.taap.2007.12.012. PMID:18313710.
5. Buckley, J.E., Clark, V.L., Meyer, T.J., and Pearlman, N.W. 1984. Hypomagnesemia after cisplatin combination chemotherapy. Arch. Intern. Med. 144(12): 2347-2348. doi:10.1001/archinte.1984. 00350220063013. PMID:6542342.
6. Dimke, H., Van der Wijst, J., Alexander, T.R., Meijer, I.M.J., Mulder, G.M., Van Goor, H., et al. 2010. Effects of the EGFR inhibitor erlotinib on magnesium handling. J. Am. Soc. Nephrol. 21(8): 1309-1316. doi:10.1681/ASN.2009111153. PMID:20595681.
7. Fakih, M.G., Wilding, G., and Lombardo, J. 2006. Cetuximabinduced hypomagnesemia in patients with colorectal cancer. Clin. Colorectal Cancer, 6(2): 152-156. doi:10.3816/CCC.2006.n.033. PMID:16945172.
8. Gill, G.N., Kawamoto, T., Cochet, C., Le, A., Sato, J.D., Masui, H., et al. 1984. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259(12): 7755-7760. PMID: 6330079.
9. Hasinoff, B.B. 2010. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244(2): 190-195. doi:10.1016/j.taap.2009.12.032. PMID: 20045709.
10. Jimeno, A., and Hidalgo, M. 2006. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim. Biophys. Acta, 1766(2): 217-229. doi:10.1016/j.bbcan. 2006.08.008. PMID:17045403.
11. Kramer, J.H., Spurney, C., Iantorno, M., Tziros, C., Mak, I.-T., Tejero-Taldo, I., et al. 2009. Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia. Am. J. Med. Sci. 338(1): 22-27. doi:10.1097/MAJ.0b013e3181aaee4d. PMID:19593099.
12. Mak, I.T., Chmielinska, J.J., Kramer, J.H., and Weglicki, W.B. 2009. AZT-induced oxidative cardiovascular toxicity: attenuation by Mg-supplementation. Cardiovasc. Toxicol. 9(2): 78-85. doi:10. 1007/s12012-009-9040-8. PMID:19484392.
13. Mak, I.T., Chmielinska, J.J., Kramer, J.H., Spurney, C.F., and Weglicki, W.B. 2011. Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: protection by substance P receptor blockade. Exp. Clin. Cardiol. 16(4): 121-124. PMID:22131854.
14. Melenhorst, W.B.W.H., Mulder, G.M., Xi, Q., Hoenderop, J.G.J., Kimura, K., Eguchi, S., and van Goor, H. 2008. Epidermal growth factor receptor signaling in the kidney: Key role in physiology and disease. Hypertension, 52(6): 987-993. doi:10.1161/HYPERTENSIONAHA.108.113860. PMID:18981331.
15. Noma, T., Lemaire, A., Naga Prasad, S.V., Barki-Harrington, L., Tilley, D.G., Chen, J., et al. 2007. Beta-arrestin-mediated beta 1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117(9): 2445-2458. doi:10.1172/JCI31901. PMID:17786238.
16. Schrag, D., Chung, K.Y., Flombaum, C., and Saltz, L. 2005. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. 97(16): 1221-1224. doi:10.1093/jnci/dji242. PMID: 16106027.
17. Tejpar, S., Piessevaux, H., Claes, K., Piront, P., Hoenderop, J.G.J., Verslype, C., and Van Cutsem, E. 2007. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 8 (5): 387-394. doi:10.1016/S1470-2045(07)70108-0. PMID: 17466895.
18. Weglicki, W.B., Mak, I.T., Chmielinska, J.J., Tejero-Taldo, M.I., Komarov, A., and Kramer, J.H. 2010. The role of magnesium deficiency in cardiovascular and intestinal inflammation. Magnes. Res. 23(4): 1-8. PMID:20971697.